Previous 10 | Next 10 |
2023-04-24 17:21:48 ET Vyant Bio ( NASDAQ: VYNT ) said its board had decided to voluntarily delist its securities from The Nasdaq Capital Market. The company said it had begun delisting and filed a Form 25 with the Securities and Exchange Commission, which is expected to becom...
CHERRY HILL, N.J., April 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to improve drug discovery for complex neurodevelopmental and neurodegenerati...
Vyant Bio ( NASDAQ: VYNT ) said that its board decided to conduct a reduction in force as soon as practical so as to preserve cash and pursue strategic alternatives and/or wind down the company, if needed. President and CEO John Roberts and Chief Scientific Officer Robe...
Continu ing to E xplore S trategic A lternatives CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for compl...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Eric Urquhart/Shutterstock.com We’re starting off the day with a breakdown of the biggest pre-market stock movers for Thursday! Moving stocks this morning are a reverse split, a crypto stock rally, and mo...
Vyant Bio ( NASDAQ: VYNT ) on Wednesday said it had engaged boutique investment bank LifeSci Capital to explore strategic alternatives for the company. Shares of the micro-cap biotech more than doubled in value to $1.60 after hours. Cherry Hill, N.J.-based VYNT is developing ...
CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company’s pro...
“Targeting specific functional rescue in a Rett patient cortical organoid disease model” CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology co...
CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental and neurodegenerative disorders. The Company...
Vyant Bio press release ( NASDAQ: VYNT ): Q3 GAAP EPS of -$0.62 beats by $0.08 . Revenue of $0.15M (-42.3% Y/Y). Shares -2.63% PM. For further details see: Vyant Bio GAAP EPS of -$0.62 beats by $0.08, revenue of $0.15M
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...